Introduction: Acquired resistance to paclitaxel, including regimens, is one of the most significant reasons for treatment failure and death in patients with ovarian cancer, but the causes of this resistance remain unclear. However, cell cycle regulation is a key mechanism by which most chemotherapeutic agents exert their cytotoxic effects. Methods: We created a paclitaxel-resistant ovarian carcinoma cell line from SKOV3 cell line, and the difference of cell cycle distribution was analyzed using flow cytometry. Analysis of human cell cycle pathway complementary DNA array was performed to identify candidate genes associated with paclitaxel resistance. Gene expression changes were validated at the messenger RNA and protein levels by real-time reverse transcriptase polymerase chain reaction and Western analysis, respectively. Results: The ratio of Gap 0 /Gap 1 phase in SKOV3-TR30 was significantly lower than that in SKOV3 (54.8% T 6.3% vs 72.7% T 7.6%, P = 0.035), and the ratio of G 2 /M phase in SKOV3-TR30 was significantly higher than that in SKOV3 (24.9% T 6.0% vs 10.2% T 3.5%, P = 0.021). Complementary DNA microarray analysis demonstrated enhanced glycogen synthase kinase-3> (GSK-3>) expression in paclitaxel-resistant ovarian carcinoma cells. Real-time reverse transcriptase polymerase chain reaction analysis revealed that the paclitaxel-resistant subline exhibited a 7.0 T 1.8Yfold increase in GSK-3> messenger RNA expression. There was a 3.34 T 0.47Yfold increase of total GSK-3 protein (GSK-3>/A) in SKOV3-TR30 cells validated by Western analysis. Conclusions: This study demonstrates that enhanced expression of GSK-3 is associated with acquired resistance to paclitaxel in ovarian carcinoma cells. Glycogen synthase kinaseY3 overexpression may probably be a significant contributor to chemoresistance.
D
espite the success obtained with the introduction of paclitaxel (taxol) in first-line chemotherapy, ovarian cancer still remains the leading cause of death in gynecological malignancies. Most patients with advanced disease, including those who achieve a complete response to first-line chemotherapy, will ultimately relapse and become unresponsive to cytotoxic therapy. 1 Acquired resistance to paclitaxel, including regimens, is one of the most significant reasons for treatment failure and death in patients with ovarian cancer. However, the mechanisms of paclitaxel resistance in cancers remain incompletely elucidated.
Cancer is frequently considered to be a disease of the cell cycle. 2 It is now becoming apparent that conventional chemotherapy drugs exert their function ultimately via the cellular machinery that controls the cell cycle and the molecular pathways that mediate the sequent cell death. 3 It is obvious that alterations of cell cycle control can create drug resistance, thereby reducing chemotherapeutic efficacy. Thus, global analysis of genes of cell cycle control by microarraybased technologies in clinical phenotype is critical to clarify molecular mechanisms for chemotherapy resistance and may help to identify potential targets for improved cancer therapies.
Glycogen synthase kinase-3 (GSK-3) is a multifunctional protein kinase known to play a pivotal role in the regulation of metabolism, embryonic development, cell differentiation, and apoptosis. 4 It also interacts with the cell cycle through the regulation of a number of cell cycle regulatory genes such as cyclin D1 and P21. 5 Two isoforms of GSK-3, GSK-3> and GSK-3A, have been identified with high homology and similar but not identical biochemical properties. 4 The dysregulation of GSK-3A has been implicated in tumorigenesis and cancer progression. 6 However, it remains controversial whether GSK-3A is a tumor promoter or a tumor suppressor. 7 Whether modulation of GSK-3 expression plays a role in the development of paclitaxel resistance in ovarian carcinoma cells remains uncertain. This study focuses on the role played by GSK-3 in paclitaxel resistance, at RNA and protein levels, in an in vitro ovarian carcinoma model of acquired paclitaxel resistance. In addition, our use of complementary DNA (cDNA) microarrays allowed identification of other candidate genes, which may be important for subsequent evaluation of paclitaxel resistance.
MATERIALS AND METHODS

Cell Lines and Cell Culture
Human ovarian carcinoma cell line SKOV3 was obtained from the American Type Culture Collection (ATCC) and maintained in McCoy's 5A medium (Gibco, Tulsa, OK) supplemented with 10% fetal bovine serum, 100-U/mL penicillin, and 100-Hg/mL streptomycin at 37-C and 5% CO 2 . Paclitaxel-resistant cell subline, SKOV3-TR30, was developed by exposing parental SKOV3 cells to increased concentration of paclitaxel as described previously.
8 SKOV3-TR30 cells demonstrated a 27.5-fold greater resistance to paclitaxel than SKOV3 cells.
Cell Cycle Analysis
Cell cycle distribution was analyzed using flow cytometry. Cells were harvested, washed twice with PBS, stained with the cell cycle analysis kit (Beckman Coulter, Brea, Calif ) according to the manufacturer's instruction, and analyzed using flow cytometry. The percentage of cells in different phases of the cell cycle was estimated using the Multicycle for Windows software (Beckman Coulter).
Analysis of Human Cell Cycle Pathway Array
Total RNA was isolated from the cell lines using Trizol reagent (Invitrogen, Carlsbad, Calif ) in accordance with the manufacturer's instructions. RNA quality was enhanced using the RNeasy Mini Kit (Qiagen, Germany), and the integrity of RNA samples were assessed qualitatively on an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, Calif). For a high-quality total RNA sample, 2 well-defined peaks corresponding to the 18S and 28S ribosomal RNAs should be observed, similar to a denaturing agarose gel, with ratios approaching 2:1 for the 28S to 18S bands (Fig. 1) . In addition, the purity of RNA was determined by measuring the absorbance at 260 and 280 nm using Du-640 spectrophotometry (Beckman). Expression of 283 genes associated with cell cycle was evaluated using human cell cycle pathway array (SBC-R-HC-102-10, National Engineering Center for Biochip, Shanghai, China) in accordance with the manufacturer's instructions.
In brief, Cy3/Cy5-labeled cDNA probes were generated from 50 Hg total RNA using oligo-(dT)15 primers for reverse transcription using Superscript II reverse transcriptase (Invitrogen). The Cy3/Cy5-labeled cDNA probes were purified using QIAquick Nucleotide Removal Kit (Qiagen). The cDNA probe was denatured by heating at 94-C for 5 minutes after incubated with human Cot-1 DNA at 70-C for 45 minutes; the cDNA probe supplied with hybridization buffer was hybridized with the cDNA membrane array at 42-C for 18 hours. The membrane was washed accordingly and then dried by centrifuge. After this, the membrane was scanned with an Agilent G2655AA scanner, and the scanned image was converted into single fluorescence image using the Split-tiff software and analyzed with the ImaGene3.0 software.
Real-Time Semi-Quantitative Reverse Transcriptase Polymerase Chain Reaction
A real-time semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was done using the ABI Prism 7000 system (ABI, Los Angeles, Calif ) to assess the expression levels of GSK-3> messenger RNA (mRNA). Total RNA was isolated, and cDNA was prepared starting from 2 Kg of total RNA using the Moloney Murine Leukemia Virus Rnase H j reverse transcriptase (Takara, Japan). Amplifications were carried out using the following primers (GSK-3>, forward 5 ¶-GGCGAGAAGAAAGACGA -3 ¶, reverse 5 ¶-CTTGACATAGAGGATAGGGA -3 ¶; A 2 -microglobulin (A 2 -M), forward 5 ¶-ACCCCCACTGAAAAA GATGA -3 ¶, reverse 5 ¶-ATCTTCAAACCTCCATGATG-3 ¶); and the SYBR Premix Ex Taq kit (Takara) in a final volume of 25 KL according to the manufacture's instructions, starting with a 10-second template denaturation step at 95-C followed by 40 cycles of 5 seconds at 95-C and 31 seconds at 60-C. Standard curves were generated using a serial dilution of the initial amount of cDNA to determine the range of template concentrations, which showed a good linearity and efficiency for the different reactions. Melt curves of the reaction products were also generated to assess the specificity of the measured fluorescence. Samples were run in triplicate, and the mean of threshold cycles (Ct) for each specimen was used to obtain the fold change of GSK-3> expression level applying the following equation:
Fold change = 2 j$($Ct) , where $Ct = Ct GSK-3> j Ct A2-M and $($Ct) = $Ct SKOV3-TR30 j $Ct SKOV3 . A fold change equal to 1 represents the resistant cell with an expression level equal to the control. To gain accuracy, 3 independent real-time RT-PCR experiments were repeated.
Western Blotting
Cells were harvested and lysed in modified protein lysis buffer (50-mmol/L Tris-HCl, pH 8.0; 150-mmol/L sodium chloride; 0.1% sodium dodecyl sulfate; 1% nonyl phenoxypolyethoxylethanol-40; and 0.02% sodium azide) added with 1% proteinase inhibitor cocktail (Sigma USA). The protein concentration was measured by the Bradford method. Equal amounts of sample lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrophoretically transferred onto a nitrocellulose membrane. The membrane was blocked with 5% nonfat dried milk in tris-buffered saline with 0.1% (vol:vol) tween 20 buffer (20-mmol/L Tris-HCl, pH 7.4; 150-mmol/L sodium chloride; and 0.1% and incubated overnight at 4-C with the antibodies against GSK-3>/A (1:150, Sigma) and A-actin (1:500, Santa Cruz Biotechnology, Santa Cruz, Calif ), respectively. The membrane was washed with TBST buffer and incubated with appropriate secondary antibodies. The protein bands were visualized using the enhanced chemiluminescence kits (Pierce USA). Signal data were normalized for A-actin bands, and a mean value was calculated from 3 independent experiments.
Statistical Analysis
Statistical analysis was performed with the SPSS 10.0 software package. All experiments were repeated 2 (microarray) or 3 times. Differences in data among treatment groups were analyzed using 1-way analysis of variance. P G 0.05 was considered statistically significant.
RESULTS
Different Cell Cycle Distributions Between Paclitaxel-Resistant and Paclitaxel-Sensitive Cell Lines
The ratio of G 0 /G 1 phase in SKOV3-TR30 was significantly lower than that in SKOV3 (54.8% T 6.3% vs 72.7% T 7.6%, P = 0.035) and the ratio of G 2 /M phase in SKOV3-TR30 was significantly higher than that in SKOV3 (24.9% T 6.0% vs 10.2% T 3.5%, P = 0.021). However, there was no significant difference between the ratio of S phase in SKOV3-TR30 and SKOV3 cells (Fig. 2, Table 1 ).
Cell Cycle cDNA Microarray Identifies GSK-3> as a Candidate Gene Associated With Paclitaxel Resistance
To identify genes associated with paclitaxel resistance, we applied a cDNA expression array to our in vitro paclitaxelresistant ovarian carcinoma model. The human cell cycle pathway array contained 283 genes that are involved in cell cycle control, including cyclin, cyclin-dependent kinase, cyclin-dependent kinase inhibitor; genes involved in mitosis, meiosis, and cytokinesis; and other genes that interacted with cell cycle. There was a 5.2-fold up-regulation of GSK-3> in SKOV3-TR30 cells as compared with the parental cells ( Table 2) . Because GSK-3 signaling is critically important in cancer and the participation of GSK-3 in paclitaxel resistance is unclear, we selected this as a candidate for the present study. In addition, there were further changes in gene expression as illustrated in Table 2 .
Expression of GSK-3> mRNA Is Increased in Paclitaxel-Resistant Ovarian Carcinoma Cell Line
To confirm the results obtained using cDNA microarrays, the expression of GSK-3> at the mRNA level was determined by real-time semi-quantitative RT-PCR analysis. In comparison with SKOV3 cells, the paclitaxel-resistant sublines exhibited a 7.0 T 1.8Yfold increase in GSK-3> mRNA expression (Fig. 3) .
Up-Regulation of GSK-3 Protein in Paclitaxel-Resistant Ovarian Carcinoma Cells
The GSK-3 expression difference between SKOV3 and SKOV3-TR30 cells was also validated at the protein level by Western analysis. It was observed that both GSK-3 > and GSK-3A protein expressions were significantly increased in paclitaxel-resistant cell line. However, no visible GSK-3> protein was detected in SKOV3 cells (Fig. 4) . There was a 3.34 T 0.47Yfold increase of total GSK-3 protein (GSK-3>/A) in SKOV3-TR30 cells (Fig. 4) .
DISCUSSION
This study is the first to demonstrate that increased GSK-3 expression is associated with acquired resistance to paclitaxel in ovarian carcinoma cells in vitro. There may be several mechanisms that are involved in this process, and that may be the result of either transcriptional or translational regulation, with modulation of gene expression and/or resultant production of the protein. Previous studies have demonstrated that inhibition of GSK-3A is sufficient to inhibit cell growth and induce apoptosis of myeloma cells, which lead to decreased pancreatic cancer cell proliferation and survival. 9, 10 It has also been reported that GSK-3A suppression sensitizes prostate cancer cells to TNF-related apoptosis-inducing ligand-induced apoptosis and GSK-3A activation may be responsible for TNF-related apoptosis-inducing ligand resistance in prostate cancer cells. 11 In addition, GSK-3A inhibition promotes adriamycin/5-FUYinduced apoptosis in human colorectal cancer cells in a p53-dependent manner. 12 Furthermore, inhibition of GSK-3A facilitates Fas-induced apoptosis activation in leukemia Jurkat cells, and depletion of GSK-3A potentiates death receptor 5-mediated apoptosis specifically in Mycexpressing cells. 13 Other studies also demonstrated that inhibition of the function of GSK-3A attenuated cell proliferation and survival in ovarian cancer, thyroid cancer, leukemia, and glioma cells. 14Y17 These studies suggest that GSK-3A activity is important for the proliferation and survival of some cancer cells, and GSK-3A is possibly an antiapoptotic molecule.
Surprisingly, several lines of evidence support GSK-3A as a proapoptotic protein. Inhibition of GSK-3A by lithium significantly reduced etoposide-and camptothecin-induced apoptosis in HepG2 hepatoma cells. 18 Activation of GSK-3A by LY294002 sensitizes hepatoma cells to chemotherapyinduced apoptosis. 19 Similarly, GSK-3A inhibition may confer resistance to cisplatin in ovarian carcinoma cell line A2780. 20 In addition, selective inhibition of GSK-3A attenuated histone deacetylase inhibitor trichostatin AYinduced cytotoxicity in MCF-7 breast cancer cells. 21 Therefore, it is likely that the most influential of these complex actions of GSK-3A on apoptosis vary depending on the cellular insult and the cell type.
The precise mechanism by which increased GSK-3 expression may lead to paclitaxel resistance is not yet fully understood. The paradoxical proapoptotic and antiapoptotic actions of GSK-3 are known to be due to GSK-3 oppositely regulating the 2 major apoptotic signaling pathways. 22 Glycogen synthase kinaseY3 promotes cell death caused by the mitochondrial intrinsic apoptotic pathway but inhibits the death receptor-mediated extrinsic apoptotic signaling pathway. When extrinsic apoptotic signaling pathway is predominant in cells exposed to some stimuli, increased GSK-3 levels may prevent cell death occurring by inhibiting the death receptorYmediated apoptosis. In our opinion, death receptorYmediated signaling pathways may play a predominant role in these cell models, although the exact mechanism of paclitaxel-induced cell apoptosis is not yet known. On the other hand, GSK-3 interacts with the cell cycle through degrading cyclin D1, which plays a critical role in G 1 progression by activating cyclin-dependent kinases 4 and 6, leading to phosphorylation of the tumor suppressor Retinoblastoma protein, with depression of E2F-mediated transcription. 23 A previous study 9 revealed that inhibition of GSK-3 triggers the melanoma cells to move from the S and G 2 /M phase to the G 0 /G 1 phase of the cell cycle. In our study, we found that the ratio of G 0 /G 1 phase in SKOV3-TR30 was significantly lower than that in SKOV3. Tumor cells with slower cell cycle progression caused by the elevated GSK-3 may exhibit the lower paclitaxel sensitivity. Continuous exposure to paclitaxel may therefore select for paclitaxel-resistant tumor cells that express increased levels of GSK-3.
In addition to GSK-3, cell cycle cDNA microarray analysis revealed several other genes with expression that may be altered in paclitaxel-resistant ovarian carcinoma cell line ( Table 2 ). These include decreased expression of cyclin A1, GRB10, FTSJ1, and others and increased expression of CDC34, CDKN2D, and others, which would affect cell cycle regulation and the consequent apoptosis in cells attacked by paclitaxel. However, these changes remain to be validated at the mRNA and protein levels.
The results from this study were obtained using focused cDNA microarrays based on cell cycle pathway that are believed to be involved in tumor progression and drug action. There are other more comprehensive cDNA microarray methods available, which produce copious amounts of data. However, our experimental approach provides a quicker, less complicated and more focused way to identify possible candidate genes. To the best of our knowledge, this is the first finding that GSK-3 protein expression is up-regulated in ovarian carcinoma cells with acquired paclitaxel resistance. Overexpression of GSK-3 probably plays a role in paclitaxel resistance in ovarian cancer. However, we acknowledge that the presentation of our results was limited because of only one cell line model. Further studies of other cell models or clinical samples with chemoresistance might support our hypothesis.
